印度瑞迪博士实验室有限公司北京代表处

制药/生物工程

外企代表处

朝阳区光华路4号东方梅地亚中心C座1210

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), herein referred to as Dr. Reddy’s, is an integrated global pharmaceutical company established in 1984, which is committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products, Dr. Reddy’s offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, bio-similars, differentiated formulations and News Chemical Entities (NCEs). The company enjoys a strong presence in the U.S., U.K., Germany, Russia and CIS, Romania, Venezuela, China, South Africa and New Zealand. Dr. Reddy’s corporate offices are located in Hyderabad, India. The total revenue of Dr. Reddy’s was USD $2.20 Billion as on 31st March, 2014. For more information, pls visit www.drreddys.com


In China, Dr. Reddy’s Laboratories Ltd. operates through its joint venture with Rotam Group of Canada. The joint venture is widely known as Kunshan Rotam Reddy Pharmaceutical Company Ltd. (KRRP) with a local manufacturing facility located in Kunshan, Jiangsu Province. KRRP was established in year 2000 complying with China laws with a total investment of USD29.99 million.